The mechanisms of tumor growth and progression involve the activation
of different processes such as neovascularization and angiogenesis. These processes
involve tumoral cells and stromal cells. Hence, inhibiting angiogenesis affects
tumor growth and proliferation in patients with different types of cancer.
Nevertheless, tumoral cells and stromal components are responsible for the resistance
to antiangiogenic therapies. The majority of tumors respond to this type of
therapy; however, some tumors may be indifferent to antiangiogenic therapies (intrinsic
resistance) and other tumors become resistant during treatment (acquired resistance).
Different strategies have been proposed to prevent resistance. Preclinical
studies and clinical trials are focused to fight this therapeutic approach in order to
prevent or delay tumor resistance to antiangiogenic therapies.
Keywords: Acquired resistance, anti-angiogenic therapy, intrinsic resistance, stromal cells, tumor cells.
Rights & PermissionsPrintExport